FY2017 Earnings Forecast for Agile Therapeutics Inc Issued By Cantor Fitzgerald (AGRX)

Agile Therapeutics Inc (NASDAQ:AGRX) – Investment analysts at Cantor Fitzgerald lowered their FY2017 earnings per share (EPS) estimates for shares of Agile Therapeutics in a research report issued on Monday, Zacks Investment Research reports. Cantor Fitzgerald analyst W. Tanner now anticipates that the specialty pharmaceutical company will earn ($0.97) per share for the year, down from their previous forecast of ($0.96). Cantor Fitzgerald has a “Buy” rating and a $5.00 price target on the stock. Cantor Fitzgerald also issued estimates for Agile Therapeutics’ FY2018 earnings at ($0.70) EPS.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03.

Several other brokerages also recently issued reports on AGRX. HC Wainwright set a $8.00 price objective on shares of Agile Therapeutics and gave the stock a “buy” rating in a research report on Friday, December 22nd. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research report on Thursday, December 28th. Janney Montgomery Scott downgraded shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 28th. William Blair downgraded shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 26th. Finally, Royal Bank of Canada reissued a “buy” rating and set a $10.00 price objective on shares of Agile Therapeutics in a research report on Wednesday, October 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $9.20.

Shares of Agile Therapeutics (NASDAQ AGRX) opened at $3.28 on Thursday. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14. Agile Therapeutics has a 12-month low of $1.93 and a 12-month high of $5.60. The stock has a market cap of $110.08, a price-to-earnings ratio of -3.57 and a beta of 2.01.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Pura Vida Investments LLC boosted its holdings in Agile Therapeutics by 65.9% during the third quarter. Pura Vida Investments LLC now owns 289,501 shares of the specialty pharmaceutical company’s stock worth $1,291,000 after purchasing an additional 115,000 shares during the last quarter. Neuberger Berman Group LLC acquired a new position in Agile Therapeutics during the third quarter worth $613,000. Alyeska Investment Group L.P. acquired a new position in Agile Therapeutics during the third quarter worth $3,747,000. Caxton Corp boosted its holdings in Agile Therapeutics by 12.1% during the third quarter. Caxton Corp now owns 1,820,012 shares of the specialty pharmaceutical company’s stock worth $8,117,000 after purchasing an additional 196,445 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new position in Agile Therapeutics during the third quarter worth $161,000. Institutional investors and hedge funds own 72.92% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “FY2017 Earnings Forecast for Agile Therapeutics Inc Issued By Cantor Fitzgerald (AGRX)” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://stocknewstimes.com/2018/01/14/cantor-fitzgerald-weighs-in-on-agile-therapeutics-incs-fy2017-earnings-agrx.html.

About Agile Therapeutics

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get a free copy of the Zacks research report on Agile Therapeutics (AGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply